CD8A and non-small cell lung carcinoma: One recent phase II study using an IL-15 superagonist (activating NK and CD-8 activity) in patients with different tumors having acquired resistance to ICIs, showed that this molecule (N803), given in combination with the same ICI in 135 patients (NSCLC 60%) has DCR of 59% and median PFS of 3,9 months with relatively low toxicity (67).